BioSpace News Archive

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc., a private biotechnology company developing senoblockers, a new class of therapeutics that can rejuvenate cells and tissues.

Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Akeso, Inc. announced that Penpulimab, an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited, has submitted a Biologics License Application to the Food and Drug Administration of the United States for third-line treatment of metastatic nasopharyngeal carcinoma.

Stemedica Cell Technologies, Inc., a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its mesenchymal stem cell technologies in the treatment of COVID-19 and additional pulmonary conditions.

With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has signed a definitive agreement to sell Myriad RBM, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, announced the closing of a $60 million Series B financing.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:00am EDT.

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome, announces additional positive data from its completed Phase II trial of LBP Blautix® in subjects with irritable bowel syndrome with constipation or with diarrhea.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced that the Company will participate in the following upcoming investor conferences